Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab and SBRT in Metastatic NSCLC
NCT03436056Phase 1Terminated
- Sponsor
- Royal Marsden NHS Foundation Trust
- Start
- Mar 2018
- Primary completion
- Jul 2019
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label trial of pembrolizumab in non-small cell lung cancer (NSCLC) (3 cohorts), sponsored by Royal Marsden NHS Foundation Trust. Primary endpoint: Proportion of Patients With Dose Limiting Toxicity at 12 weeks. Started Mar 2018; status: terminated.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03436056.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03436056.